Safety of Prolia (Denosumab) in Kidney Transplant Recipients on Immunosuppression

Key Safety Considerations

The American Thoracic Society recommends monitoring patients on mycophenolate for signs of infection, including fever, cough, respiratory changes, and neurologic symptoms, due to significant infection risks associated with mycophenolate 1, 2
The standard kidney transplant regimen, including tacrolimus, mycophenolate, and corticosteroids, creates a baseline state of significant immunosuppression, according to the Kidney International guidelines 3

The American College of Chest Physicians recommends monitoring CBC counts every 1-3 months as standard for mycophenolate therapy, and screening for BK polyomavirus monthly for the first 3-6 months, then every 3 months through the first year 1, 2, 4
The Kidney International guidelines suggest maintaining CMV prophylaxis for at least 3 months post-transplant, extended to 6 weeks after any T-cell depleting antibody therapy 4

The American College of Chest Physicians considers denosumab appropriate for patients with severe osteoporosis requiring potent antiresorptive therapy, or when bisphosphonates are contraindicated or poorly tolerated 2
The Kidney International guidelines recommend ensuring stable graft function and absence of active rejection before initiating denosumab, and verifying no active infections, particularly opportunistic infections 1, 2, 5

The American College of Chest Physicians advises avoiding live vaccines while on mycophenolate, as patients will have inadequate immunologic response, and maintaining lowest effective immunosuppression doses by 2-4 months post-transplant if no rejection has occurred 1, 2, 5
The Kidney International guidelines suggest optimizing the kidney transplant regimen before adding denosumab, with tacrolimus as the first-line calcineurin inhibitor, and mycophenolate maintained at effective doses unless toxicity mandates reduction 3, 5